280 related articles for article (PubMed ID: 25988934)
21. Ebola virus dynamics in mice treated with favipiravir.
Madelain V; Oestereich L; Graw F; Nguyen TH; de Lamballerie X; Mentré F; Günther S; Guedj J
Antiviral Res; 2015 Nov; 123():70-7. PubMed ID: 26343011
[TBL] [Abstract][Full Text] [Related]
22. Interferon-γ Inhibits Ebola Virus Infection.
Rhein BA; Powers LS; Rogers K; Anantpadma M; Singh BK; Sakurai Y; Bair T; Miller-Hunt C; Sinn P; Davey RA; Monick MM; Maury W
PLoS Pathog; 2015; 11(11):e1005263. PubMed ID: 26562011
[TBL] [Abstract][Full Text] [Related]
23. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.
Haque A; Hober D; Blondiaux J
Antimicrob Agents Chemother; 2015 Oct; 59(10):5892-902. PubMed ID: 26248374
[TBL] [Abstract][Full Text] [Related]
24. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model.
Huggins J; Zhang ZX; Bray M
J Infect Dis; 1999 Feb; 179 Suppl 1():S240-7. PubMed ID: 9988190
[TBL] [Abstract][Full Text] [Related]
25. Development of therapeutics for treatment of Ebola virus infection.
Li H; Ying T; Yu F; Lu L; Jiang S
Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
[TBL] [Abstract][Full Text] [Related]
26. Ebola virus: the search for vaccines and treatments.
Wilson JA; Bosio CM; Hart MK
Cell Mol Life Sci; 2001 Nov; 58(12-13):1826-41. PubMed ID: 11766882
[TBL] [Abstract][Full Text] [Related]
27. Teicoplanin inhibits Ebola pseudovirus infection in cell culture.
Wang Y; Cui R; Li G; Gao Q; Yuan S; Altmeyer R; Zou G
Antiviral Res; 2016 Jan; 125():1-7. PubMed ID: 26585243
[TBL] [Abstract][Full Text] [Related]
28. Dose regimen of favipiravir for Ebola virus disease.
Mentré F; Taburet AM; Guedj J; Anglaret X; Keïta S; de Lamballerie X; Malvy D
Lancet Infect Dis; 2015 Feb; 15(2):150-1. PubMed ID: 25435054
[No Abstract] [Full Text] [Related]
29. A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus.
McCarthy SD; Majchrzak-Kita B; Racine T; Kozlowski HN; Baker DP; Hoenen T; Kobinger GP; Fish EN; Branch DR
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004364. PubMed ID: 26752302
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin.
Kolokoltsov AA; Adhikary S; Garver J; Johnson L; Davey RA; Vela EM
Arch Virol; 2012 Jan; 157(1):121-7. PubMed ID: 21947546
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Inhibition of Ebola Virus Progeny Production by Antiviral Compounds.
Falzarano D
Methods Mol Biol; 2017; 1628():203-210. PubMed ID: 28573622
[TBL] [Abstract][Full Text] [Related]
32. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE
J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335
[TBL] [Abstract][Full Text] [Related]
33. Progress towards the treatment of Ebola haemorrhagic fever.
Ströher U; Feldmann H
Expert Opin Investig Drugs; 2006 Dec; 15(12):1523-35. PubMed ID: 17107278
[TBL] [Abstract][Full Text] [Related]
34. Small molecule inhibitors of ebola virus infection.
Picazo E; Giordanetto F
Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
[TBL] [Abstract][Full Text] [Related]
35. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.
Swenson DL; Warfield KL; Warren TK; Lovejoy C; Hassinger JN; Ruthel G; Blouch RE; Moulton HM; Weller DD; Iversen PL; Bavari S
Antimicrob Agents Chemother; 2009 May; 53(5):2089-99. PubMed ID: 19223614
[TBL] [Abstract][Full Text] [Related]
36. Targeting Ebola virus replication through pharmaceutical intervention.
Hansen F; Feldmann H; Jarvis MA
Expert Opin Investig Drugs; 2021 Mar; 30(3):201-226. PubMed ID: 33593215
[No Abstract] [Full Text] [Related]
37. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.
Geisbert TW; Hensley LE; Jahrling PB; Larsen T; Geisbert JB; Paragas J; Young HA; Fredeking TM; Rote WE; Vlasuk GP
Lancet; 2003 Dec; 362(9400):1953-8. PubMed ID: 14683653
[TBL] [Abstract][Full Text] [Related]
38. The natural compound silvestrol is a potent inhibitor of Ebola virus replication.
Biedenkopf N; Lange-Grünweller K; Schulte FW; Weißer A; Müller C; Becker D; Becker S; Hartmann RK; Grünweller A
Antiviral Res; 2017 Jan; 137():76-81. PubMed ID: 27864075
[TBL] [Abstract][Full Text] [Related]
39. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.
Towner JS; Paragas J; Dover JE; Gupta M; Goldsmith CS; Huggins JW; Nichol ST
Virology; 2005 Feb; 332(1):20-7. PubMed ID: 15661137
[TBL] [Abstract][Full Text] [Related]
40. [Current status of drug treatment against the disease caused by the Ebola virus].
Reina J
Rev Esp Quimioter; 2016 Feb; 29(1):1-7. PubMed ID: 26785224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
